Updates in Management of Advanced Renal Cell Carcinoma: Making Sense of the Menu

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 75 Minutes

Overview

This program offers a comprehensive exploration of advanced clear cell renal cell carcinoma (RCC) management, focusing on approved frontline combinations of immunotherapy and/or targeted therapy, insights into HIF2-alpha involvement in RCC pathogenesis, and strategies for managing treatment-related adverse events.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Identify the approved frontline combinations of immunotherapy and/or targeted therapy in advanced clear cell renal cell carcinoma and gain insights into the factors guiding the selection between these combinations for individual patients

2. Discuss the involvement of hypoxia-inducible factor-2 alpha (HIF2-alpha) in the pathogenesis of renal cell carcinoma (RCC) and the role of HIF2α inhibition in the management of metastatic disease

3. Distinguish between adverse events associated with immunotherapy and those related to targeted therapy, and comprehend the strategies for managing these adverse events in patients with RCC.    

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
Course opens: 
04/19/2024
Course expires: 
04/19/2025
Cost:
$0.00
Rating: 
0

Faculty

Jacqueline Brown, MD

Dr. Brown is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University and a genitourinary medical oncologist. She attended medical school at the University of Rochester School of Medicine and Dentistry and completed her internal medicine residency at the University of Virginia, followed by a chief resident year and a Hematology and Medical oncology fellowship at Emory University, where she served as chief fellow in her final year of training. She is a clinical investigator with special interests in urothelial cancer and improving the treatment of genitourinary cancers in older adults. She serves as the Associate Medical Director of the Ambulatory Infusion Center at Winship Cancer Institute and a Core Faculty member for the Internal Medicine Residency Program at Emory.

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Jacqueline Brown, MD discloses contracted research with Medicenna, Xencor, Surface, Oncology but these relationships have ended during the past 24 months.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.

Price

Cost:
$0.00
Please login or register to take this course.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test
  4. Submit the evaluation form

DISCLAIMER:

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above